Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06212479 · ClinicalTrials.gov registry record
An Observational Study On TheAccuracy Of Whole-Body Magnetic Resonance Imaging (Wb-Mri) ScreeningTo Predict Clinically Significant Diagnoses In General Population Subjects Interested In Proactive And Advanced General Preventive Healthcare.
A clinical trial of Cancer and Metabolic Disease, sponsored by Hercules.
- Recruiting
- Registry status
- 100,000
- Enrollment target
- 1
- Study location
NCT06212479: Recruiting study of Cancer and Metabolic Disease, sponsored by Hercules.
NCT06212479 is a study of Cancer and Metabolic Disease that is actively recruiting participants, run by Hercules. The registered enrollment target is 100,000 participants, above the 3,329-participant average among 615 other Cancer trials with a reported enrollment target (2904% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06212479, a study of Cancer and Metabolic Disease, is actively recruiting participants, sponsored by Hercules.
- RECRUITING
- Registry status
- 100,000 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective, single-arm, observational study capturing data from whole-body magnetic resonance imagining (WB-MRI) from up to 100,000 male and female subjects 18 years of age or older recruited at multiple clinical sites within the United States. Study subjects must meet a set of inclusion and exclusion criteria. Potential subjects arriving at the study sites will be evaluated for enrollment. It is the Principal Investigator's (PI) responsibility to enroll only subjects who satisfy the inclusion/exclusion criteria. Recruitment can occur by subject presentation at the sites for elective standard screening, word-of-mouth, flyers, healthcare professional (HCP) referrals, advertisement online, or any other means, subject to approval by the associated institutional review board (IRB) or ethics committee (EC) when applicable.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST MRI Scan
Study Locations (1)
Massachusetts
- Hercules Research Center - Watertown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100,000 participants |
| Start Date | 2024-05-17 |
| Est. Completion | 2037-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06212479
The ClinicalTrials.gov registry entry for NCT06212479 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 100,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 3,329-participant average among 615 other Cancer trials with a reported enrollment target (2904% higher). The listed sponsor is Hercules, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which MRI Scan is the first listed.
NCT06212479 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06212479 about?
NCT06212479 is a clinical study titled "An Observational Study On TheAccuracy Of Whole-Body Magnetic Resonance Imaging (Wb-Mri) ScreeningTo Predict Clinically Significant Diagnoses In General Population Subjects Interested In Proactive And Advanced General Preventive Healthcare.". This is a prospective, single-arm, observational study capturing data from whole-body magnetic resonance imagining (WB-MRI) from up to 100,000 male and female subjects 18 years of age or older recruited at multiple clinical sites within the United States. Study subjects must meet a set of inclusion ...
What is the current status of trial NCT06212479?
This trial is currently recruiting. The enrollment target is 100,000 participants. The study started on 2024-05-17. Estimated completion is 2037-01.
What conditions does trial NCT06212479 study?
This clinical trial studies the following conditions: Cancer, Metabolic Disease, Neurologic Disorder, Aneurysm.
What interventions are being tested in trial NCT06212479?
The interventions under investigation include: MRI Scan (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06212479?
This trial is sponsored by Hercules, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06212479 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Registry Study to Evaluate the Clinical Outcome of Cancer Patients and Benign Diseases Treated with Radiation
RECRUITING
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
A Natural History Study of Metabolic Sizing in Health and Disease
RECRUITING
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
Long-Term Follow-Up of Recipient of Gene Transfer Research
RECRUITING
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.